Dendritic Cell Activation Found to Boost Efficacy of T Cell Immunotherapies
Australian researchers found that T cells engineered to express the dendritic cell growth factor Flt3L overcame an important obstacle to the treatment of solid tumors.
Cancer
Jounce Regains Worldwide Rights to LILRB2 Inhibitor JTX-8064 from BMS
Rights to the antibody candidate JTX-8064 have been transferred from Bristol-Myers Squibb back to Jounce Therapeutics effective June 3rd 2020.
MDSC Metabolite Found to Underly Immunosuppression, May Aid Cancer Therapy
TUM researchers have found that methylglyoxal underlies MDSC-mediated immunosuppression with implications for cancer diagnosis and treatment.
CAR-T Therapy Yescarta Leads to High Response Rate in Non-Hodgkin Lymphoma
Interim analysis of the ZUMA-5 trial found that Yescarta showed efficacy for treating relapsed or refractory indolent non-hodgkin lymphoma.
FDA Accepts IND Application for Agenus’ iNKT Therapy agenT-797
Agenus has announced the acceptance of an IND application for iNKT therapy agenT-797 by the FDA with human trials to start in 2020.
AVEO Oncology Submits NDA to FDA for Tivozanib in Renal Cell Carcinoma
The NDA submission is intended to support the approval of Tivozanib as a treatment for adult renal cell carcinoma in the United States.
Roche’s Tecentriq Approved by FDA for PD-L1 High Non-Small Cell Lung Cancer
Tecentriq (atezolizumab) has been approved by the FDA as a first-line treatment for adult PD-L1-high metastatic non-small cell lung cancer.
Oncolytics Biotech: Phase 1 Trial Data of Pelareorep for Colorectal Cancer
Oncolytics Biotech has announced a publication demonstrating positive data for Pelareorep, FOLFIRI, and bevacizumab in colorectal cancer.
Opdivo and Yervoy Improve Survival in Metastatic Non-Small Cell Lung Cancer
The phase 3 CheckMate 9LA trial by Bristol Myers Squibb evaluated the efficacy of Opdivo and Yervoy for treating non-small cell lung cancer.
Surface Oncology Partners with Merck for Phase 1 Trial of anti-CD39 SRF617
Surface Oncology will contribute anti-CD39 SRF617 and Merck anti-PD-1 Keytruda in the phase 1/1b trial involving patients with solid tumors.